Secondary primary malignancies in multiple myeloma: An old nemesis revisited

Advances in Hematology

Volumn 2012, Issue , 2012, Pages

  Yang, Jay ^a   Terebelo, Howard R ^b   Zonder, Jeffrey A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PROVIDENCE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARMUSTINE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RISK; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; SECOND CANCER;

EID: 84864939793     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2012/801495     Document Type: Review

References (66)

1. Curtis R. E., Freedman D. M., Ron E., New malignancies among cancer survivors: SEER cancer registries, 19732000 NIH Publication 2006 05-5302 Bethesda, Md, USA National Cancer Institute
2. Olivanen T., Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study European Journal of Haematology 2000 65 2 123 127 (Pubitemid 30615087)
3. Dong C., Hemminki K., Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 19581996: a search for common mechanisms British Journal of Cancer 2001 85 7 997 1005 (Pubitemid 33016003)
4. Bergsagel D. E., Sprague C. C., Austin C., Griffith K. M., Evaluation of new chemotherapeutic agents in the treatment of multiple myelomaIV. L-Phenylalanine mustard (NSC-8806) Cancer Chemotherapy Reports. Part 1 1962 21 87 99
5. Hoogstraten B., Sheehe P. R., Cuttner J., Cooper T., Kyle R. A., Oberfield R. A., Townsend S. R., Harley J. B., Hayes D. M., Costa G., Holland J. F., Melphalan in multiple myeloma Blood 1967 30 1 74 83
6. MacLennan I. C. M., Cusick J., Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis British Journal of Cancer 1985 52 2 153 158 (Pubitemid 15229348)
7. Oken M. M., Harrington D. P., Abramson N., Kyle R. A., Knospe W., Glick J. H., Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479 Cancer 1997 79 8 1561 1567 (Pubitemid 27154788)
8. Blade J., San Miguel J. F., Alcala A., Maldonado J., Sanz M. A., Garcia-Conde J., Moro M. J., Alonso C., Besalduch J., Zubizarreta A., Besses C., Gonzalez-Brito G., Hernandez-Martin J., Fernandez-Calvo J., Rubio D., Ortega F., Jimenez R., Colominas P., Faura M. V., Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients Journal of Clinical Oncology 1993 11 6 1165 1171 (Pubitemid 23163359)
9. Alexanian R., Balcerzak S., Haut A., Remission maintenance therapy for multiple myeloma Archives of Internal Medicine 1975 135 1 147 152
10. Belch A., Shelley W., Bergsagel D., Wilson K., Klimo P., White D., Willan A., A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients British Journal of Cancer 1988 57 1 94 99 (Pubitemid 18067112)
11. Kyle R. A., Pierre R. V., Bayrd E. D., Multiple myeloma and acute myelomonocytic leukemia New England Journal of Medicine 1970 283 21 1121 1125
12. Rosner F., Gruenwald H., Multiple myeloma terminating in acute leukemia. Report of 12 cases and review of the literature American Journal of Medicine 1974 57 6 927 939
13. Cleary B., Binder R. A., Kales A. N., Veltri B. J., Simultaneous presentation of acute myelomonocytic leukemia and multiple myeloma Cancer 1978 41 4 1381 1386 (Pubitemid 8330417)
14. Dispenzieri A., Lacy M. Q., Greipp P. R., Greer J. P., Foerster J., Rodgers G. M., Multiple myeloma Wintrobe's Clinical Hematology 2009 Philadelphia, Pa, USA Wolters Kluwer Health/Lippincott Williams Wilkins 2417 2418
15. Cuzick J., Erskine S., Edelman D., Galton D. A. G., A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis British Journal of Cancer 1987 55 5 523 529 (Pubitemid 17098861)
16. Greene M. H., Harris E. L., Gershenson D. M., Melphalan may be a more potent leukemogen than cyclophosphamide Annals of Internal Medicine 1986 105 3 360 367 (Pubitemid 16014300)
17. Attal M., Harousseau J. L., Stoppa A. M., Sotto J. J., Fuzibet J. G., Rossi J. F., Casassus P., Maisonneuve H., Facon T., Ifrah N., Payen C., Bataille R., A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New England Journal of Medicine 1996 335 2 91 97 (Pubitemid 26240110)
18. Pasquini M. C., Wang Z., Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides. 2011, http://www.cibmtr.org
19. Miller J. S., Arthur D. C., Litz C. E., Neglia J. P., Miller W. J., Weisdorf D. J., Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy Blood 1994 83 12 3780 3786 (Pubitemid 24175569)
20. Pedersen-Bjergaard J., Andersen M. K., Christiansen D. H., Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation Blood 2000 95 11 3273 3279 (Pubitemid 30428453)
21. Forrest D. L., Nevill T. J., Naiman S. C., Le A., Brockington D. A., Barnett M. J., Lavoie J. C., Nantel S. H., Song K. W., Shepherd J. D., Sutherland H. J., Toze C. L., Davis J. H., Hogge D. E., Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis Bone Marrow Transplantation 2003 32 9 915 923 (Pubitemid 37369270)
22. Govindarajan R., Jagannath S., Flick J. T., Vesole D. H., Sawyer J., Barlogie B., Tricot G., Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma British Journal of Haematology 1996 95 2 349 353 (Pubitemid 26360224)
23. Harrison C. N., Gregory W., Vaughan Hudson G., Devereux S., Goldstone A. H., Hancock B., Winfield D., MacMillan A. K., Hoskin P., Newland A. C., Milligan D., Linch D. C., High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML British Journal of Cancer 1999 81 3 476 483 (Pubitemid 29458802)
24. Barlogie B., Tricot G., Haessler J., Van Rhee F., Cottler-Fox M., Anaissie E., Waldron J., Pineda-Roman M., Thertulien R., Zangari M., Hollmig K., Mohiuddin A., Alsayed Y., Hoering A., Crowley J., Sawyer J., Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989 Blood 2008 111 1 94 100
25. Moreau P., Facon T., Attal M., Hulin C., Michallet M., Maloisel F., Sotto J. J., Guilhot F., Marit G., Doyen C., Jaubert J., Fuzibet J. G., Franois S., Benboubker L., Monconduit M., Voillat L., Macro M., Berthou C., Dorvaux V., Pignon B., Rio B., Matthes T., Casassus P., Caillot D., Najman N., Grosbois B., Bataille R., Harousseau J. L., Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial Blood 2002 99 3 731 735 (Pubitemid 34525530)
26. Bartlett J. B., Dredge K., Dalgleish A. G., The evolution of thalidomide and its IMiD derivatives as anticancer agents Nature Reviews Cancer 2004 4 4 314 322 (Pubitemid 38525287)
27. European Medicines Agency, Withdrawal assessment report for lenalidomide Celgene Europe. 2008, http://www.ema.europa.eu/docs/enGB/documentlibrary/ Applicationwithdrawalassessmentreport/2010/01/WC500065821.pdf
28. Ads L., Le Bras F., Sebert M., Kelaidi C., Lamy T., Dreyfus F., Eclache V., Delaunay J., Bouscary D., Visanica S., Turlure P., Bresler A. G., Cabrol M.-P., Banos A., Blanc M., Vey N., Delmer A., Wattel E., Chevret S., Fenaux P., Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies Haematologica 2012 97 2 213 218
29. Fenaux P., Giagounidis A., Selleslag D., Beyne-Rauzy O., Mufti G., Mittelman M., Muus P., Te Boekhorst P., Sanz G., Del Caizo C., Guerci-Bresler A., Nilsson L., Platzbecker U., Lbbert M., Quesnel B., Cazzola M., Ganser A., Bowen D., Schlegelberger B., Aul C., Knight R., Francis J., Fu T., Hellstrm-Lindberg E., A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q Blood 2011 118 14 3765 3776
30. Davies F., Baz R., Lenalidomide mode of action: linking bench and clinical findings Blood Reviews 2010 24 1 S13 S19
31. Quach H., Ritchie D., Stewart A. K., Neeson P., Harrison S., Smyth M. J., Prince H. M., Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma Leukemia 2010 24 1 22 32
32. Palumbo A., Freeman J., Weiss L., Fenaux P., The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes Expert Opinion on Drug Safety 2012 11 1 107 120
33. Mitsiades N., Mitsiades C. S., Poulaki V., Chauhan D., Richardson P. G., Hideshima T., Munshi N. C., Treon S. P., Anderson K. C., Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications Blood 2002 99 12 4525 4530 (Pubitemid 34627223)
34. Chang D. H., Liu N., Klimek V., Hassoun H., Mazumder A., Nimer S. D., Jagannath S., Dhodapkar M. V., Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications Blood 2006 108 2 618 621 (Pubitemid 44061362)
35. Kotla V., Goel S., Nischal S., Heuck C., Vivek K., Das B., Verma A., Mechanism of action of lenalidomide in hematological malignancies Journal of Hematology and Oncology 2009 2, article 36
36. Ito T., Ando H., Suzuki T., Ogura T., Hotta K., Imamura Y., Yamaguchi Y., Handa H., Identification of a primary target of thalidomide teratogenicity Science 2010 327 5971 1345 1350
37. Zhu Y. X., Braggio E., Shi C.-X., Bruins L. A., Schmidt J. E., Van Wier S., Chang X.-B., Bjorklund C. C., Fonseca R., Bergsagel P. L., Orlowski R. Z., Stewart A. K., Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide Blood 2011 118 18 4771 4779
38. Boultwood J., Pellagatti A., McKenzie A. N. J., Wainscoat J. S., Advances in the 5q-syndrome Blood 2010 116 26 5803 5811
39. Mitsiades C. S., How immunomodulatory are IMIDs? Blood 2011 117 5 1440 1441
40. Salmon S. E., Crowley J. J., Balcerzak S. P., Roach R. W., Taylor S. A., Rivkin S. E., Samlowski W., Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group study Journal of Clinical Oncology 1998 16 3 890 896 (Pubitemid 28108720)
41. Alexanian R., Weber D., Dimopoulos M., Delasalle K., Smith T. L., Randomized trial of -interferon or dexamethasone as maintenance treatment for multiple myeloma American Journal of Hematology 2000 65 3 204 209
42. Shustik C., Belch A., Robinson S., Rubin S. H., Dolan S. P., Kovacs M. J., Grewal K. S., Walde D., Barr R., Wilson J., Gill K., Vickars L., Rudinskas L., Sicheri D. A., Wilson K., Djurfeldt M., Shepherd L. E., Ding K., Meyer R. M., A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7 British Journal of Haematology 2007 136 2 203 211 (Pubitemid 46020747)
43. Berenson J. R., Crowley J. J., Grogan T. M., Zangmeister J., Briggs A. D., Mills G. M., Barlogie B., Salmon S. E., Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients Blood 2002 99 9 3163 3168 (Pubitemid 34525294)
44. Badros A. Z., The role of maintenance therapy in the treatment of multiple myeloma Journal of the National Comprehensive Cancer Network 2010 8 1 S21 S27
45. Barlogie B., Tricot G., Anaissie E., Shaughnessy J., Rasmussen E., Van Rhee F., Fassas A., Zangari M., Hollmig K., Pineda-Roman M., Lee C., Talamo G., Thertulien R., Kiwan E., Krishna S., Fox M., Crowley J., Thalidomide and hematopoietic-cell transplantation for multiple myeloma New England Journal of Medicine 2006 354 10 1021 1030 (Pubitemid 43357806)
46. Attal M., Harousseau J. L., Leyvraz S., Doyen C., Hulin C., Benboubker L., Agha I. Y., Bourhis J. H., Garderet L., Pegourie B., Dumontet C., Renaud M., Voillat L., Berthou C., Marit G., Monconduit M., Caillot D., Grobois B., Avet-Loiseau H., Moreau P., Facon T., Maintenance therapy with thalidomide improves survival in patients with multiple myeloma Blood 2006 108 10 3289 3294
47. Abdelkefi A., Ladeb S., Torjman L., Ben Othman T., Lakhal A., Ben Romdhane N., El Omri H., Elloumi M., Belaaj H., Jeddi R., Aissaou L., Ksouri H., Ben Hassen A., Msadek F., Saad A., Hsari M., Boukef K., Amouri A., Louzir H., Dellagi K., Ben A., Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial Blood 2008 111 4 1805 1810 (Pubitemid 351451485)
48. Spencer A., Prince H. M., Roberts A. W., Prosser I. W., Bradstock K. F., Coyle L., Gill D. S., Horvath N., Reynolds J., Kennedy N., Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure Journal of Clinical Oncology 2009 27 11 1788 1793
49. Lokhorst H. M., Van Der Holt B., Zweegman S., Vellenga E., Croockewit S., Van Oers M. H., Von Dem Borne P., Wijermans P., Schaafsma R., De Weerdt O., Wittebol S., Delforge M., Berenschot H., Bos G. M., Jie K. S. G., Sinnige H., Van Marwijk-Kooy M., Joosten P., Minnema M. C., Van Ammerlaan R., Sonneveld P., A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma Blood 2010 115 6 1113 1120
50. Morgan G. J., Jackson G. H., Davies F. E., Maintenance thalidomide may improve progression free but not overall survival; results from the myeloma IX maintenance randomisation ASH Annual Meeting Abstracts 2008 112 11 656
51. Cavo M., Pantani L., Tacchetti P., Pallotti M. C., Brioli A., Petrucci A., Zamagni E., Tosi P., Thalidomide maintenance in multiple myeloma: certainties and controversies Journal of Clinical Oncology 2009 27 32 e186 e187
52. Palumbo A., Bringhen S., Rossi D., Cavalli M., Larocca A., Ria R., Offidani M., Patriarca F., Nozzoli C., Guglielmelli T., Benevolo G., Callea V., Baldini L., Morabito F., Grasso M., Leonardi G., Rizzo M., Falcone A. P., Gottardi D., Montefusco V., Musto P., Petrucci M. T., Ciccone G., Boccadoro M., Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial Journal of Clinical Oncology 2010 28 34 5101 5109
53. Mateos M. V., Oriol A., Martnez-Lpez J., Gutiérrez N., Teruel A. I., de Paz R., Garca-Laraa J., Bengoechea E., Martn A., Mediavilla J. D., Palomera L., de Arriba F., Gonzlez Y., Hernndez J. M., Sureda A., Bello J. L., Bargay J., Pealver F. J., Ribera J. M., Martn-Mateos M. L., Garca-Sanz R., Cibeira M. T., Ramos M. L. M., Vidriales M. B., Paiva B., Montalbn M. A., Lahuerta J. J., Bladé J., Miguel J. F. S., Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial The Lancet Oncology 2010 11 10 934 941
54. Attal M., Lauwers-Cances V., Marit G., Caillot D., Moreau P., Facon T., Stoppa A. M., Hulin C., Benboubker L., Garderet L., Decaux O., Leyvraz S., Vekemans M.-C., Voillat L., Michallet M., Pegourie B., Dumontet C., Roussel M., Leleu X., Mathiot C., Payen C., Avet-Loiseau H., Harousseau J.-L., Lenalidomide maintenance after stem-cell transplantation for multiple myeloma New England Journal of Medicine 2012 366 19 1782 1791
55. McCarthy P. L., Owzar K., Hofmeister C. C., Hurd D. D., Hassoun H., Richardson P. G., Giralt S., Stadtmauer E. A., Weisdorf D. J., Vij R., Moreb J. S., Callander N. S., Van Besien K., Gentile T., Isola L., Maziarz R. T., Gabriel D. A., Bashey A., Landau H., Martin T., Qazilbash M. H., Levitan D., McClune B., Schlossman R., Hars V., Postiglione J., Jiang C., Bennett E., Barry S., Bressler L., Kelly M., Seiler M., Rosenbaum C., Hari P., Pasquini M. C., Horowitz M. M., Shea T. C., Devine S. M., Anderson K. C., Linker C., Lenalidomide after stem-cell transplantation for multiple myeloma New England Journal of Medicine 2012 366 19 1770 1781
56. Palumbo A., Hajek R., Delforge M., Kropff M., Petrucci M. T., Catalano J., Gisslinger H., Wiktor-Jdrzejczak W., Zodelava M., Weisel K., Cascavilla N., Iosava G., Cavo M., Kloczko J., Bladé J., Beksac M., Spicka I., Plesner T., Radke J., Langer C., Yehuda D. B., Corso A., Herbein L., Yu Z., Mei J., Jacques C., Dimopoulos M. A., Continuous lenalidomide treatment for newly diagnosed multiple myeloma New England Journal of Medicine 2012 366 19 1759 1769
57. Palumbo A. P., Delforge M., Catalano J., Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older ASCO Meeting Abstracts 2011 29 15, supplement, 8007
58. Dimopoulos M. A., Richardson P. G., Brandenburg N., Yu Z., Weber D. M., Niesvizky R., Morgan G. J., A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide Blood 2012 119 12 2764 2767
59. Rossi A. C., Mark T. M., Jayabalan D., Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM) ASCO Meeting Abstracts 2011 29 15, supplement, 8008
60. Reece D. E., Masih-Khan E., Goswami R. S., Incidence and characteristics of secondary myelodysplastic syndrome developing during lenalidomide-based regimens in relapsed and/or refractory multiple myeloma patients ASH Annual Meeting Abstracts 2010 116 21, 1877
61. Mailankody S., Pfeiffer R. M., Kristinsson S. Y., Korde N., Bjorkholm M., Goldin L. R., Turesson I., Landgren O., Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS) Blood 2011 118 15 4086 4092
62. Landgren O., Ma W., Kyle R. A., Rajkumar S. V., Korde N., Albitar M., Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma Leukemia 2012 26 4 844 845
63. Dimopoulos M. A., Chen C., Spencer A., Niesvizky R., Attal M., Stadtmauer E. A., Petrucci M. T., Yu Z., Olesnyckyj M., Zeldis J. B., Knight R. D., Weber D. M., Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma Leukemia 2009 23 11 2147 2152
64. Zonder J. A., Crowley J., Hussein M. A., Bolejack V., Moore D. F., Whittenberger B. F., Abidi M. H., Durie B. G. M., Barlogie B., Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232) Blood 2010 116 26 5838 5841
65. Landgren O., Thomas A., Mailankody S., Myeloma and second primary cancers New England Journal of Medicine 2011 365 23 2241 2242
66. Kyle R. A., Pierre R. V., Bayrd E. D., Multiple myeloma and acute leukemia associated with alkylating agents Archives of Internal Medicine 1975 135 1 185 192